JNJ - Johnson & Johnson

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

5 Large Drug Stocks to Watch From a Thriving Industry

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Johnson & Johnson (JNJ) Stock Moves 0.01%: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $154.37, marking a +0.01% move from the previous day.

• 
  TSMC (TSM) Stock Moves -1.19%: What You Should Know

  Zacks
• 
  Wells Fargo (WFC) Stock Moves -0.61%: What You Should Know

  Zacks

The Zacks Analyst Blog Highlights InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare

InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

• 
  NIKE, Inc. (NKE) Is a Trending Stock: Facts to Know Before Betting on It

  Zacks
• 
  Here is What to Know Beyond Why Tesla, Inc. (TSLA) is a Trending Stock

  Zacks

Buy the Dip On These Warren Buffett Stocks

If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Want Passive Income Forever? Buy These 2 Magnificent Stocks Now

Many investors actively seek dividend stocks, and who can blame them? Choosing the right dividend stocks is arguably the best way to avoid this risk: Not all dividend stocks are created equal. With that said, let's turn our attention to two companies that are practically passive income machines and will likely continue rewarding shareholders with payout increases for a long time: Johnson & Johnson (NYSE: JNJ) and Apple (NASDAQ: AAPL).

Solid Earnings Fuel Potential Bull Market in Medical Devices

CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.

When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?

Johnson & Johnson (JNJ) Stock Moves -0.1%: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $156.66, moving -0.1% from the previous trading session.

• 
  Johnson & Johnson (JNJ) Stock Moves 0.01%: What You Should Know

  Zacks
• 
  IBM (IBM) Stock Moves 0.46%: What You Should Know

  Zacks

Better Buy: Medtronic vs. Johnson & Johnson

Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.

Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash

Johnson & Johnson (NYSE: JNJ) and Dollar General (NYSE: DG) are traditionally strong, defensive stocks. Both companies deliver stable earnings, low volatility, and -- last but certainly not least -- dependable dividends. Johnson & Johnson stock traditionally has done well during downturns compared to the rest of the market.

Got $1,000? 5 Buffett Stocks to Buy and Hold Forever

It's hard to beat Warren Buffett's knack for making money, which is why so many investors keep a sharp eye on the stocks Buffett buys through his holding company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). Of the nearly 50 stocks Buffett currently owns, here are five you might want to buy now and hold forever. Johnson & Johnson (NYSE: JNJ) is one of the longest-held stocks in Buffett's portfolio, and there are solid reasons you also might want to buy and hold this healthcare stock.

3 Relatively Safe Stocks to Buy if a Recession Is on the Way

Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.

Kenvue Just IPO'd, but Is the Stock a Buy?

With its listing on the New York Stock Exchange on May 4 and the conclusion of its initial public offering (IPO) on May 8, Kenvue (NYSE: KVUE) is finally a separate entity from Johnson & Johnson (NYSE: JNJ). The IPO raised net proceeds of $4.2 billion, and it marks the birth of a new giant within the consumer health products industry. In case you aren't familiar, Kenvue owns the rights to dozens of popular consumer health brands like Listerine, Aveeno, Tylenol, Motrin, Baby Powder, and even Band-Aids.

Johnson & Johnson (JNJ) Down 2.2% Since Last Earnings Report: Can It Rebound?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

2 Dividend Stocks to Double Up On Right Now

The continued bear market in stocks has a silver lining. Johnson & Johnson (NYSE: JNJ) and Prologis (NYSE: PLD) are great stocks to double up on right now for those with a low allocation to these leading dividend payers. Meanwhile, investors who don't own them yet should consider adding them to their portfolio.

3 No-Brainer Stocks to Buy With $1,000 Right Now

This makes every sizable downturn in equities a buying opportunity for patient investors. What's more, most online brokerages have completely done away with commission fees and minimum deposit requirements, which makes it easier than ever for everyday investors to put their money to work on Wall Street. The first stock that makes for a smart buy with the major stock indexes well off their all-time highs is Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG), the parent company of internet search engine Google, streaming platform YouTube, and autonomous vehicle company Waymo, among other subsidiaries.

Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows

If you're buying a dividend stock that's trading near its low for the year, it stands to reason that the yield is also higher than it would normally be. The tough part is ensuring you have found a quality stock. Three that qualify are Johnson & Johnson (NYSE: JNJ), Paychex (NASDAQ: PAYX), and Keurig Dr Pepper (NASDAQ: KDP).

J&J's proposed talc settlement would pay $400 million to US state AGs

Johnson & Johnson has set aside $400 million to resolve U.S. state consumer protection actions as part of its broader $8.9 billion effort to settle claims that its Baby Powder and other talc products cause cancer. J&J subsidiary LTL Management filed a bankruptcy plan in New Jersey late on Monday that details how the company intends to pay different types of cancer victims in a bankruptcy settlement. J&J has said that its talc products are safe and do not cause cancer.

Kenvue Has Gone Public: Should You Buy the Stock?

Johnson & Johnson (NYSE: JNJ) officially spun off its consumer health business this month, creating the largest U.S. initial public offering since 2021. Kenvue (NYSE: KVUE) began trading as a stand-alone business and gives healthcare investors a new stock to potentially add to their portfolios. Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business.

Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average dividends. Neither stock has performed particularly well this year, with Johnson & Johnson's shares down more than 9% in 2023 and UnitedHealth's shares down more than 7%. UnitedHealth is the nation's largest private health insurer, with more than 400,000 employees.

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

• 
  Here is What to Know Beyond Why PlayAGS, Inc. (AGS) is a Trending Stock

  Zacks
• 
  Cigna Group (CI) is Attracting Investor Attention: Here is What You Should Know

  Zacks